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Abstract
We consider a system of two coupled integro-differential equations modelling pop-
ulations of healthy and cancer cells under therapy. Both populations are structured
by a phenotypic variable, representing their level of resistance to the treatment. We
analyse the asymptotic behaviour of the model under constant infusion of drugs. By
designing an appropriate Lyapunov function, we prove that both densities converge to
Dirac masses. We then define an optimal control problem, by considering all possible
infusion protocols and minimising the number of cancer cells over a prescribed time
frame. We provide a quasi-optimal strategy and prove that it solves this problem for
large final times. For this modelling framework, we illustrate our results with numeri-
cal simulations, and compare our optimal strategy with periodic treatment schedules.
1 Introduction
One of the primary causes of death worldwide is cancer [63]. Cancer treatment encounters
two main pitfalls: the emergence of drug resistance in cancer cells and toxic side effects
to healthy cells. Given these causes of treatment failure, designing optimized therapeutic
strategies is a major objective for oncologists. In this paper, we propose a mathematical
framework for modelling these phenomena and optimally combining therapies.
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1.1 Overview and motivation
The most frequently used class of anti-cancer drugs are chemotherapeutic (cytotoxic) drugs,
which are toxic to cells, leading to cell death. For example, platinum-based agents kill
dividing cells by causing DNA damage and disrupting DNA replication [36]. Another class
of drugs are cytostatic drugs, which slow down cell proliferation without killing cells. For
example, trastuzumab is a cytostatic drug used in breast cancer treatment that targets
growth factor receptors present on the surface of cells, and inhibits their proliferation [33].
Despite this obvious functional difference between the two classes, cytostatic drugs, such
as tyrosine kinase inhibitors, can also be cytotoxic at high doses [56].
It is a well documented fact that cytotoxic agents can fail to control cancer growth and
relapse [30, 50, 58]. First, eradication of the tumour cell population is compromised by the
emergence of drug resistance, due to intrinsic or acquired genotypic and phenotypic het-
erogeneity in the cancer cell population [5, 10, 28, 49], because a subpopulation of resistant
cells survives and proliferates, even in the presence of further treatment with identical [61],
or higher doses [53]. Second, chemotherapeutic treatments have unwanted side effects on
healthy cells, which precludes unconstrained treatment use for fear of unwanted toxicities
to major organs. It is therefore a challenge for oncologists to optimally and safely treat
patients with chemotherapy.
The medical objective of killing cancer cells together with preserving healthy cells from
excessive toxicity is routinely translated in mathematical terms as finding the best thera-
peutic strategies (i.e., below some maximum tolerated dose, referred to as MTD) in order
to minimise an appropriately chosen cost function. There are many works in mathemati-
cal oncology focusing on the optimal modulation of chemotherapeutic doses and schedules
designed to control cancer growth, e.g. [2, 17, 18, 37, 41, 39, 40, 38, 65, 66, 67].
Since using ordinary differential equations (ODEs) is a common technique for modelling the
temporal dynamics of cell populations, the mathematical field of optimal control applied to
ODEs has emerged as an important tool to tackle such questions (see for instance [60] for
a complete presentation). In these ODE models, toxicity can either be incorporated in the
cost functional as in [18], or by adding the dynamics of the healthy cells [7]. One simple,
but rather coarse, paradigm used to represent drug resistance in such ODE models is by
distinguishing between sensitive and resistant cancer cell subpopulations [18, 41]. Herein,
the main tools available to obtain rigorous results are the Pontryagin maximum principle
(PMP) and geometric optimal control techniques [1, 54, 59, 68].
Another paradigm used in the mathematical modelling of drug resistance relies on the
idea that phenotypic heterogeneity in cancer cells and the dynamics of cancer cell popula-
tions can be understood through the principles of Darwinian evolution [27, 29]. Given a
particular tumor micro- and macro-environment (e.g., access to oxygen, nutrients, growth
factors, drug exposure), the fittest cells are selected. In the case of resistance, resistant cell
subpopulations are assumed to emerge and be selected for their high levels of fitness in the
presence of chemotherapeutic agents. Whether they already exist in the cell population,
surviving and remaining dormant at clinically undetectable small numbers, and emerging
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only by natural selection, or they do not exist at all initially, but emerge as a result of
an evolutionary trade-off between proliferation and development of costly survival mech-
anisms [3], likely of epigenetic nature, is still difficult to decide. The two scenarios have
been studied in a modelling framework in [15].
Adaptive dynamics is a branch of mathematical biology that aims at modelling Darwinian
selection [21, 22]. It is thus a natural theoretical framework for the representation of phe-
notypic evolution in proliferating cell populations exposed to anti-cancer drugs and tumor
micro-environmental factors. Non-Darwinian evolutionary principles have also been pro-
posed to take into account drug resistance phenomena [52]. Adaptive dynamics is amenable
to modelling these principles as well. To this end, stochastic or game-theoretic points of
view (see [13, 32]) are standard in adaptive dynamics. Apart from ODEs, partial differential
equations (PDEs) and integro-differential equations (IDEs) represent other deterministic
approaches. The latter ones represent the focus of our paper. For an introduction to PDE
and IDE models in adaptive dynamics, we refer the interested reader to [51, 46].
A common feature of these modelling techniques is that the population is structured by
a trait, referred to as phenotype. The resistance level of a cell to a drug therapy is an
example of such trait. Often, this variable is assumed to be continuous since it is corre-
lated with biological characteristics, e.g., the intracellular concentration of a detoxication
molecule (such as reduced glutathione), the activity of detoxifying enzymes in metabolising
the administered drug, or drug efflux transporters eliminating the drug. Another possi-
ble continuous structuring variable is the ability of some cancer cells to quickly change
their phenotypes (otherwise said, their intrinsic plasticity) by regulating the level of DNA
methylation and/or of activity of DNA methyltransferases [14, 57]. This ability is also
correlated with the degree of resistance to a given drug.
To this end, a relevant modelling alternative to the binary sensitive versus resistant ODE
framework (as already proposed long ago in e.g., [17, 18]) consists of studying the cells at
the population level using structured population dynamics. Specifically, let us denote the
density of cells at time t and with phenotype x by n(t, x), with x ∈ [0, 1]. The continuous
phenotype x represents an abstract level of resistance (which may be molecularly related to
the activity level of an ABC transporter, or to a mean level of methylation of the DNA) to
a cytotoxic drug in a cell population. Such models allow for the analysis of the asymptotic
behaviour in terms of an asymptotically selected phenotype and of the total population
ρ(t) :=
∫ 1
0 n(t, x) dx. In the classical non-local logistic model, written as the IDE
∂n
∂t
(t, x) =
(
r(x)− d(x)ρ(t)
)
n(t, x),
where ρ(t) :=
∫ 1
0 n(t, x) dx, cells proliferate at rate r(x) and die at rate d(x)ρ(t) (the
more individuals, the more competition and thus death). Such equations have well known
asymptotic properties, such as convergence and concentration [51, 20, 34]. For large times,
ρ converges to the smallest value ρ∞ such that r−dρ∞ 6 0 on [0, 1] and n(t, ·) concentrates
on the set of points such that r(x)−d(x)ρ∞ = 0. The limit is thus typically expected to be
a sum of Dirac masses. This phenomenon can be interpreted as the selection of dominant
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traits by the environment. A common strategy for proving this asymptotic behaviour
consists in showing that ρ has a bounded variation (BV ) on [0,+∞), as in [46, 47].
To the best of our knowledge, general results of convergence and concentration are still
elusive for systems of IDEs: the methods used in the BV framework do not seem to
generalise, even in the setting that is of special interest to us, namely in the case of two
competitively interacting populations of (healthy and cancer) cells. This leads to the
asymptotic analysis of systems of the form
∂n1
∂t
(t, x) =
(
r1(x)− d1(x)I1(t)
)
n1(t, x),
∂n2
∂t
(t, x) =
(
r2(x)− d2(x)I2(t)
)
n2(t, x).
(1)
The competitive coupling comes from I1 = a11ρ1 + a12ρ2, I2 = a22ρ2 + a21ρ1 with ρi(t) =∫ 1
0 ni(t, x) dx, i = 1, 2. In particular, it is not clear a priori whether such interactions may
or may not lead to oscillatory behaviours at the level of ρ1, ρ2. We mention the work [11]
where convergence and concentration are completely characterized for a 2x2 system, where
a triangular coupling structure is considered. Due to an appropriately designed Lyapunov
function, the results of our paper imply that convergence and concentration hold for the
model (1).
Our goal here is also to include control terms in order to model the effect of the drugs on
the proliferation and death rates. The equations we will use henceforth throughout this
paper are
∂n1
∂t
(t, x) =
(
r1(x)
1 + α1v(t)
− d1(x)I1(t)− µ1(x)u(t)
)
n1(t, x),
∂n2
∂t
(t, x) =
(
r2(x)
1 + α2v(t)
− d2(x)I2(t)− µ2(x)u(t)
)
n2(t, x).
(2)
Here the asymptotic analysis is more complex because of the controls u and v. On a
fixed time-frame (0, T ), we will search among controls u, v in BV (0, T ), since it would not
biologically feasible to impose fast varying drug infusion rates to patients.
The main difference between the approach developed in this paper and the ODE ones is
that the model considered throughout is an IDE approach studied from an optimal control
perspective. This model is inspired by [45, 44] where an IDE model (possibly with an
additional space variable) has been used in order to model the effect of constant doses of
cytotoxic and cytostatic drug chemotherapies.
However, a mathematical proof of the failure of chemotherapeutic treatments at MTD
levels to eradicate cancer cell population has not yet been formulated in the IDE modelling
framework, a result that we will obtain in the present study. In addition, previous works
have only considered a priori prescribed drug treatment schedules.
In this paper, we show that our model (2) is consistent with clinical observations on the
effect of constant infusion of high doses, and we address the optimal control problem of such
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IDE models. Our study has a potential impact for oncologists and mathematical biologists,
since it provides an accurate and robust understanding of possible optimal strategies. Up
to our knowledge, this is the first time that a mathematical model and its optimal control
reflect the emerging fact, observed and acknowledged recently by many clinicians, that
giving maximal tolerated drug doses, even periodically, may finally be detrimental and in
any case is far from being an optimal strategy in view of curing cancer.
1.2 Modelling and overview of the main results
We consider both the healthy and cancer cell populations, modelled by their respective
densities nH(t, x) and nC(t, x), where the variable x ∈ [0, 1], called phenotype, represents
drug resistance levels: a cell of phenotype x is highly sensitive if x is close to 0, and is
highly resistant if x is close to 1. Chemotherapy is modelled by two functions of time
u1 and u2, representing cytotoxic and cytostatic drug infusion flows, respectively, in the
two cell populations. These functions are the controls, assumed to be bounded variation
functions of time if the equation is set on a bounded time-frame, subject to maximum
tolerated doses (MTD) thresholds:
0 6 u1(t) 6 u
max
1 , 0 6 u2(t) 6 u
max
2 . (3)
We assume that the densities nH and nC satisfy the following lDE system:
∂nH
∂t
(t, x) = RH (x, ρH(t), ρC(t), u1(t), u2(t))nH(t, x),
∂nC
∂t
(t, x) = RC (x, ρC(t), ρH(t), u1(t), u2(t))nC(t, x),
(4)
with the net growth rates defined as
RH(x, ρH , ρC , u1, u2) :=
rH(x)
1 + αHu2
− dH(x)IH − u1µH(x),
RC(x, ρC , ρH , u1, u2) :=
rC(x)
1 + αCu2
− dC(x)IC − u1µC(x),
(5)
the non-local coupling as
IH := aHHρH + aHCρC , IC := aCHρH + aCCρC , (6)
with
ρH(t) =
∫ 1
0
nH(t, x) dx, ρC(t) =
∫ 1
0
nC(t, x) dx,
which are the total number of healthy and tumour cells at time t.
The system starts from the initial conditions
nH(0, x) = n
0
H(x), nC(0, x) = n
0
C(x). (7)
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In the above model:
• rH and rC are the drug-free proliferation rates, assumed to be positive, decreasing
functions on [0, 1].
• The factors 11+αHu2(t) and
1
1+αCu2(t)
model the decrease in proliferation rates due to
cytostatic drugs. The positive constants αH and αC represent average sensitivities of cells
to cytostatic drugs. Throughout, we make the assumption that cancer cells are more
sensitive to the drugs, i.e.,
αH < αC . (8)
• The terms dH IH and dC IC are the drug-free death rates. The functions dH and
dC are positive, decreasing functions on [0, 1]. Given the dependence in IH and IC , the
model resembles a logistic one. According to their definitions, these functions are linear
combinations of the total population ρH and ρC , i.e., we consider both intraspecific and
interspecific competition. We assume that the intraspecific competition is stronger than
the interspecific one:
0 < aHC < aHH , 0 < aCH < aCC . (9)
• The terms u1(t)µH(x) and u1(t)µC(x) are additional death rates due to cytotoxic drugs,
with µH and µC assumed to be non-negative, decreasing functions on [0, 1]. These functions
may vanish on some interval [1 − ε, 1], which in this case reflects the fact that some cells
become fully resistant to those drugs.
• This model imposes that the phenotype x be mostly linked to the resistance to cytotoxic
drugs, in accordance with [53]. This fact which will be made clearer by the analysis of the
model (see below among the consequences of Theorem 1).
Asymptotic behaviour for controls in BV ([0,+∞)). Our first aim is to show that
our model reproduces the following clinical observations: when high drug doses are admin-
istered, the tumour first reduces in size before regrowing, insensitive to further treatment.
We thus want to establish asymptotic properties of the model, a challenging task since it is
similar to system (2). The following statement is our first main result: we achieve a com-
plete description of the asymptotic behaviour of system (4), with a class of asymptotically
constant controls.
Theorem 1. Let u1, u2 be any functions in BV ([0,+∞)), and let ū1, ū2 be their limits at
+∞. Then, for any positive initial population of healthy and of tumour cells, (ρH(t), ρC(t))
converges to some equilibrium point (ρ∞H , ρ
∞
C ), which can be explicitly computed.
Furthermore, nH and nC concentrate on a set of points which can also be explicitly com-
puted.
The explicit values can be found in Section 2, where this result is proved. If ū1 = 0, the
sets of points on which nH and nC concentrate are independent of ū2. This is due to the
fact that the phenotypic variable x models resistance to cytotoxic drugs.
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Thus, system (4) also exhibits convergence and concentration: the classical features of a
single IDE generalise to a system, and our method is flexible enough to incorporate controls
in BV ([0,+∞)). The main ingredient of the proof is an appropriately designed Lyapunov
function, inspired by [34] and by the classical Lyapunov functions used for studying the
global asymptotical stability of steady-states in Lotka-Volterra ODE systems, as in [26].
The proof then consists of a fine analysis of this Lyapunov functional, yielding both con-
vergence and concentration, while providing estimates on their speed. This method is new
in the analysis of such IDE systems.
If µC vanishes identically on some interval [1−ε, 1] (meaning that full resistance is possible),
this theorem explains why, in the long run, high doses are not optimal. This means that
our mathematical conclusions are in agreement with the idea that the standard method
used in the clinic, namely administering maximum tolerated doses, should be reconsidered.
Alternatives are currently extensively being investigated by oncologists, e.g., metronomic
scheduling, which relies on frequent and continuous low doses of chemotherapy [6, 12, 50].
Theorem 1 thus motivates the optimal control problem of searching for the best possible
functions u1 and u2 to minimise the number of cancer cells within a given horizon of time,
which we now introduce in more details.
Optimal control problem: optimal chemotherapy strategy. We fix some T > 0,
and assume that the initial conditions n0H and n
0
C are continuous and positive functions
on [0, 1]. For any (u1, u2) in (BV (0, T ))2 which satisfy (3), we consider the associated
trajectory (nH(·, x), nC(·, x)) on [0, T ], solution of the system (4) starting from (n0H , n0C).
We also take into account two state constraints:
• it is required to keep a minimal proportion of healthy cells with respect to the total
number of cells, and hence we impose that
ρH(t)
ρH(t) + ρC(t)
> θHC , (10)
for some 0 < θHC < 1.
• Moreover, we impose that the number of healthy cells always remains above a certain
fraction of the initial number of healthy cells:
ρH(t) ≥ θHρH(0), (11)
for some 0 < θH < 1.
We define AT as the set of admissible controls, i.e., for which those constraints are satisfied
on (0, T ). For given (u1, u2) ∈ AT , we define the associated cost as the number of cancer
cells at the end of the time-frame:
CT (u1, u2) := ρC(T ). (12)
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We now define the optimal control problem, denoted in short (OCP) in the sequel, as
inf
(u1,u2)∈AT
CT (u1, u2). (13)
In other words, we want to find the best drug administration strategy to minimise the
number of cancer cells at the end of a fixed time-frame [0, T ], while both keeping toxicity
to a tolerable level and controlling tumor size. It might seem more natural to study the
problem in free final time, but as explained later on, the mapping T 7−→ ρC(T ) (where
ρC(T ) is the optimal value obtained by solving (OCP) on [0, T ]) is decreasing in T . This
implies that the optimal control problem in free final time T is ill-posed and does not admit
any solution. The other implication is that when solving the optimal control problem in
free final time tf under the constraint tf 6 T (where T is a horizon), then the optimal
solution will be such that tf = T . This is why we focus on an optimal control problem in
fixed final time.
In this paper, we perform a thorough study of (OCP), both theoretically and numerically.
The theoretical study is made on a smaller class of controls which, after a long phase of
constant doses, are allowed to vary on a small final time frame. More precisely, for a given
T1 < T , we consider the subclass BT ⊂ AT defined by
BT :=
{
(u1, u2) ∈ AT , (u1(t), u2(t)) = (ū1, ū2) on (0, T1), T − T1 6 TM2
}
where T is large and where the optimal length of the second phase T2 := T −T1 is bounded
above by some small constant TM2 . Thus, the first phase is long. Optimising within this
class is equivalent to searching for constant optimal values ū1, ū2 of the controls during
the first phase, the length of the second phase T2 6 TM2 , and optimal BV (T1, T ) controls
u1, u2 on (T1, T ). The reason for this restriction to this class of controls comes from the
answer to the following question: given a specific tumour size (i.e., a given number of
cancer cells), what would be the optimal phenotypic cellular distribution in order tumor
burden at the end of the time interval? Proposition 1 shows that, for a very short time,
it is always better that the cancer cell population be concentrated on some appropriate
phenotype, i.e., that the initial population be a Dirac mass at some appropriate point.
From Theorem 1, we know that it is possible to asymptotically reach Dirac masses with
constant controls. The combination of these two results justifies the analysis in BT .
In this class of controls, our second main result characterises a quasi-optimal strategy in
large time, a result which we now state informally.
Consider the problem of minimising ρC(T ) within the class BT . When T is large enough,
the optimal strategy approximately consists of:
• a first long-time arc, with constant controls on [0, T1], at the end of which populations
have almost concentrated in phenotype (for T large);
• a last short-time part, on [T1, T ] consisting of at most three arcs (for small T2 =
T − T1):
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- a boundary arc1
- a free arc with controls u1 = umax1 and u2 = u
max
2 ;
- a boundary arc along the constraint (11) with u2 = umax2 .
The precise result and hypotheses are given by Theorem 2 in Section 3.
In order for Theorem 2 to hold, an important assumption we make is that when cancer
cells are concentrated on a sensitive phenotype, the maximum tolerated doses will kill more
cancer cells than healthy ones. Without this assumption, it is not clear whether one can
expect the same strategy to be optimal, nor whether the patient can efficiently be treated.
We also emphasise that, for these IDEs, a PMP can be established but would not lead to
tractable equations. The key property to still be able to identify the optimal strategy in
BT is that the long first phase allows us to use Theorem 1: both populations concentrate
and their dynamics on the last phase are (approximately) governed by ODEs, as proved
in Lemma 5. The second phase can thus be analysed with ODE techniques, here the
Pontryagin maximum principle (see [1, 54, 69]). This is done in Proposition 2.
More concretely, Theorem 2 says that:
To optimally treat a cancer, the quasi-optimal strategy consists of:
• first, administering constant doses to the patient, over a long time. The
role of the first long-time arc is to allow the cancer cell population to
concentrate on a sensitive phenotype. From a mathematical point of view,
this means that the healthy and tumour cell populations (almost) converge
to a Dirac mass.
• second, during a short-time phase, following a strategy composed of at
most three arcs. If the first phase is such that the constraint (10) is
saturated, then there can be a first arc along this constraint. The maximal
amount of drugs is administered until the constraint (11) saturates. The
last arc is along this constraint, with an appropriately chosen cytotoxic
drug infusion which leads to a further decrease of the number of cancer
cells.
Numerically, we solve the problem (OCP) in AT . The simulations confirm the theoretical
results and show that, with the chosen set of parameters, the strategy indeed approximately
consists of these two phases for T large. We also compare the optimal strategy with a
periodic one, and verify that the former performs better than the latter.
Furthermore, the numerical results suggest that for generic parameters, the optimal choice
of constant controls on the first phase is such that the constraint (10) is saturated. Thus,
the second phase possibly starts on this constraint.
1A boundary arc (for the state constraint g (ρH , ρC) 6 0) is an arc along which g (ρH , ρC) = 0, i.e., the
constraint is saturated. A free arc is an arc along which g (ρH , ρC) < 0, i.e., the constraint is not saturated.
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Another important property highlighted by the numerical simulations is that, given the
choice of parameters made, ρC can decrease arbitrarily close to 0 once the cancer cell
population has concentrated on a sensitive enough phenotype. We thus find a strategy for
which T 7−→ ρC(T ) is decreasing to 0; hence, there would be no solution to (OCP) if the
final time T were let free.
This is the first time that a mathematical model based on integro-differential equations
demonstrates that, within our modeling framework, immediate administration of maximal
tolerated drug doses, or a periodic treatment schedule, is an optimal solution for eradicating
cancer. Here, we prove that it is better to allow the phenotypes to concentrate, before
administering maximal doses. Such a strategy is much more efficient. This is also a
message to be conveyed to clinicians, who have become increasingly aware of such facts.
The paper is organised as follows. Section 2 is devoted to the proof of Theorem 1 and
to numerical simulations showing how the model can reproduce the regrowth of a cancer
cell population. Using these results, we have theoretical and numerical grounds for our
claim that constant doses are sub-optimal and we then turn our attention to (OCP). In
Section 3, several arguments are given to justify the restriction to the class BT , with a long
first phase. The rest of the section is then devoted to proving Theorem 2. The numerical
solutions of (OCP) in AT are provided in Section 4. They are compared to periodic
strategies. In Section 5, we conclude with several comments and open questions.
2 Constant infusion strategies
This section is devoted to the asymptotic analysis of the IDE model (4), in order to
specifically understand the effect of giving constant doses on the long run. We start by
considering one equation only, for which relatively simple and well known arguments are
sufficient to conclude that both convergence and concentration hold.
2.1 Asymptotics for healthy or cancer cells alone
In this section, we assume that n0H = 0 and that n
0
C is continuous and positive on [0, 1].
We have the following result of convergence and concentration for constant controls and
cancer cells alone. Of course, we have a similar statement for healthy cells alone.
Lemma 1. Assume that u1 and u2 are constant: u1 ≡ ū1, and u2 ≡ ū2, and assume that
rC
1 + αC ū2
− ū1µC > 0 on [0, 1]. (14)
Then the total population of cancer cells ρC(t) converges to ρ∞C > 0, which is the smallest
nonnegative real number such that
rC
1 + αC ū2
− ū1µC 6 dCaCCρ∞C on [0, 1]. (15)
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Let BC ⊂ [0, 1] be the set of points such that the equality holds in (15). Then nC(t, ·)
concentrates on BC as t goes to +∞. In particular, if BC is reduced to a singleton x∞C ,
then nC(t, ·) converges to ρ∞C δx∞C inM
1(0, 1).
Here and in the sequel, δx denotes the Dirac mass at x, andM1(0, 1) is the set of Radon
measures supported in [0,1].
The proof of this lemma is rather classical, its main ingredient is proving that ρ is a BV
function to obtain convergence, and concentration follows. It is done in Appendix A.
Remark 1. As it clearly appears in the proof, the result holds for more general initial
conditions in L∞(0, 1). One only needs to require that they are bounded from below by a
positive constant on a neighbourhood of one of the points of BC .
2.2 Asymptotics for the complete model: proof of Theorem 1
Now, let us take into account the complete coupling between healthy and tumour cells.
For the remaining part of this article, we assume for simplicity that both n0H and n
0
C
are continuous and positive on [0, 1] (although it is possible to be slightly more general,
see Remark 1), but we emphasise that we no longer require assumption (14). A further
technical assumption is needed to prove that convergence and concentration hold, namely
that the functions are Lipschitz continuous:
rH , rC , dH , dC , µH , µC ∈ C0,1(0, 1). (16)
In two dimensions and with constant controls ū1, ū2, the previous technique of proving
that ρ is BV cannot be extended. As for a single equation, however, we can integrate the
equations with respect to x to obtain upper bounds for ρH and ρC . For example, let us
integrate the equation defining ρH and bound as follows:
dρH(t)
dt
6
∫ 1
0
(
rH(x)− dH(x)aHHρH(t)
)
nH(t, x) dx.
Thus, we clearly have lim supt→+∞ ρi 6 ρmaxi := maxx
ri
aiidi
for i = H,C.
It also still holds with the reasoning made in the proof of Lemma 1 that if ρH and ρC
converge, then the limits must be the solution of the (invertible) system
aHHρ
∞
H + aHCρ
∞
C = I
∞
H ,
aCHρ
∞
H + aCCρ
∞
C = I
∞
C .
(17)
where I∞H > 0 is the smallest nonnegative real number such that
rH(x)
1 + αH ū2
− ū1µH(x) 6 dH(x)I∞H , (18)
and I∞C > 0 is the smallest nonnegative real number such that
rC(x)
1 + αC ū2
− ū1µC(x) 6 dC(x)I∞C . (19)
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Furthermore, if this convergence holds true, then nH (resp. nC) concentrate on AH (resp.
AC) defined as
AH =
{
x ∈ [0, 1], rH(x)
1 + αH ū2
− ū1µH(x)− dH(x)I∞H = 0
}
,
AC =
{
x ∈ [0, 1], rC(x)
1 + αC ū2
− ū1µC(x)− dC(x)I∞C = 0
}
.
Proof of Theorem 1.
First step: definition of the Lyapunov functional.
We adapt a strategy developed in [34]. We choose any couple of measures (n∞H , n
∞
C ) in
M1(0, 1) satisfying
∫ 1
0 n
∞
i (x) dx = ρ
∞
i , i = H,C which furthermore satisfy
supp(n∞H ) ⊂ AH , supp(n∞C ) ⊂ AC . (20)
For i = H,C, and mi := 1di , let us define the Lyapunov functional as
V (t) := λHVH(t) + λCVC(t),
where
Vi(t) =
∫ 1
0
mi(x)
[
n∞i (x) ln
(
1
ni(t, x)
)
+ (ni(t, x)− n∞i (x))
]
dx,
with positive constants λH and λC to be adequately chosen later.
Second step: computation and sign of the derivative.
In what follows, we skip dependence in t in the functions RH and RC to increase readability.
We have
dVH
dt
=
∫ 1
0
mH(x)
[
−n∞H (x)
∂tnH(t, x)
nH(t, x)
+ ∂tnH(t, x)
]
dx
=
∫ 1
0
mH(x)RH (x, ρH , ρC , u1, u2) [nH(t, x)− n∞H (x)] dx
=
∫ 1
0
mH(x) (RH (x, ρH , ρC , u1, u2)−RH (x, ρ∞H , ρ∞C , u1, u2)) [nH(t, x)− n∞H (x)] dx
+
∫ 1
0
mH(x)RH (x, ρ
∞
H , ρ
∞
C , u1, u2) [nH(t, x)− n∞H (x)] dx
The first term is simply∫ 1
0
mH(x) (RH (x, ρH , ρC , u1, u2)−RH (x, ρ∞H , ρ∞C , u1, u2)) [nH(t, x)− n∞H (x)]
=
∫ 1
0
mH(x)dH(x) [aHH(ρ
∞
H − ρH) + aHC(ρ∞C − ρC)] [nH(t, x)− n∞H (x)] dx
= −aHH(ρ∞H − ρH)2 − aHC(ρ∞C − ρC)(ρ∞H − ρH)
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The second term can also be written as
BH(t) :=
∫ 1
0
mH(x)RH (x, ρ
∞
H , ρ
∞
C , u1, u2) [nH(t, x)− n∞H (x)] dx
=
∫ 1
0
mH(x)RH (x, ρ
∞
H , ρ
∞
C , ū1, ū2) [nH(t, x)− n∞H (x)] dx
+
∫ 1
0
mH(x) (RH (x, ρ
∞
H , ρ
∞
C , u1, u2)−RH (x, ρ∞H , ρ∞C , ū1, ū2)) [nH(t, x)− n∞H (x)] dx
=
∫ 1
0
mH(x)RH (x, ρ
∞
H , ρ
∞
C , ū1, ū2)nH(t, x) dx
+
∫ 1
0
mH(x)
[
rH(x)
(
1
1 + αHu2
− 1
1 + αH ū2
)
+ µH(x)(ū1 − u1)
]
[nH(t, x)− n∞H (x)] dx,
where we use (20) for the last equality. Note that the first term in the last expression is
nonpositive by definition of (ρ∞H , ρ
∞
C ), and the second goes to 0 as t goes to +∞. Conse-
quently, the decomposition
Bi = B̃i + Ei, i = H,C, (21)
holds, with B̃H , B̃C nonpositive, and EH , EC which asymptotically vanish. This decom-
position will be important in the last step.
Eventually, we have:
dV
dt
= −1
2
XTMX + λHBH + λCBC (22)
with M = ATD +DA, X =
(
ρ∞H − ρH
ρ∞C − ρC
)
, D =
(
λH 0
0 λC
)
and A =
(
aHH aHC
aCH aCC
)
.
We first look for a choice of constants λH , λC that ensures that the symmetric matrix M ,
is also positive semi-definite.
Since M =
(
2λHaHH λHaHC + λCaCH
λHaHC + λCaCH 2λCaCC
)
has positive trace, both its eigen-
values are non-negative provided that its determinant is non-negative. Now, det(M) =
4λHλCaHHaCC−(λHaHC + λCaCH)2, and we see that choosing λH := 1aHC and λC :=
1
aCH
leads to
det(M) = 4
aHHaCC − aHCaCH
aHCaCH
> 0
using the assumption (9).
Our aim is to prove that −1
2
XTMX converges to 0 as t goes to +∞, which will yield the
convergence of (ρH , ρC). Concentration of (nH , nC) then follows easily with the arguments
developed in the proof of Lemma 1 .
Third step: lower estimate for V.
To estimate V from below, we need a uniform (in x) upper bound on nH , nC . Because
of the regularity assumption made on the data (functions are Lipschitz continuous), there
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exists C > 0 such that:
∀(x, y) ∈ [0, 1], RH (y, ρH , ρC , u1, u2) > RH (x, ρH , ρC , u1, u2)− C|x− y|,
C can be chosen to be independent of t since ρH , ρC , u1, and u2 are all bounded.
This implies that∫ 1
0
nH(t, y) dy =
∫ 1
0
n0H(y) exp
(∫ t
0
RH (y, ρH , ρC , u1, u2) ds
)
dy
>
∫ 1
0
n0H(y)
n0H(x)
(
n0H(x) exp
(∫ t
0
RH (x, ρH , ρC , u1, u2)
))
exp (−Ct|x− y|) dy
>
nH(t, x)
n0H(x)
∫ 1
0
exp (−Ct|x− y|) dy
Using the boundedness of ρH and n0H (C has changed and is independent of t and x)
and computing the integral, we can write: for t large enough, nH(t, x) 6 Ct. Similarly,
nC(t, x) 6 Ct.
The bound on V follows immediately:
V (t) > −C (ln(t) + 1) . (23)
We now define another function, close to dVdt , whose behaviour will allow us to conclude.
Fourth step: estimates on dVdt .
We set
G := −1
2
XTMX + 2 (λHBH + λCBC) .
The first term is:
−1
2
XTMX = −λHaHH(ρ∞H − ρH)2 − λCaCC(ρ∞C − ρC)2
− (λHaHC + λCaCH)(ρ∞H − ρH)(ρ∞C − ρC),
so that (writing in short RH for RH(x, ρH , ρC , u1, u2) and RC for RC(x, ρC , ρH , u1, u2)):
d
dt
(
−1
2
XTMX
)
= (ρ∞H − ρH)
[
2λHaHH
∫ 1
0
RHnH + (λHaHC + λCaCH)
∫ 1
0
RCnC
]
+ (ρ∞C − ρC)
[
2λCaCC
∫ 1
0
RCnC + (λHaHC + λCaCH)
∫ 1
0
RHnH
]
Let us now differentiate BH and BC using the expression that initially defines them:
dBH
dt
=
∫ 1
0
mH(x)RH(x, ρ
∞
H , ρ
∞
C , u1, u2)RH(x, ρH , ρC , u1, u2)nH(t, x) dx
−
∫ 1
0
mH(x)
(
αHrH(x)
1
(1 + αHu2)
2
du2
dt
+ µH(x)
du1
dt
)
[nH(t, x)− n∞H (x)] dx
14
Using the following estimate
mH(x)RH(x, ρ
∞
H , ρ
∞
C , u1, u2) RH(x, ρH , ρC , u1, u2)
> mH(x) (RH(x, ρ
∞
H , ρ
∞
C , u1, u2)−RH(x, ρH , ρC , u1, u2))RH(x, ρH , ρC , u1, u2)
= − [aHH(ρ∞H − ρH) + aHC(ρ∞C − ρC)]RH(x, ρH , ρC , u1, u2),
we obtain the inequality
dBH
dt
> −λH [aHH(ρ∞H − ρH) + aHC(ρ∞C − ρC)]
∫ 1
0
RHnH
−
∫ 1
0
mH(x)
(
rH(x)
1
(1 + αHu2)
2
du2
dt
+ µH(x)
du1
dt
)
[nH(t, x)− n∞H (x)] dx
and similarly for BC . We thus obtain (the terms in aHH and aCC cancel each other out):
dG
dt
> (ρ∞H − ρH)
[
(λHaHC + λCaCH − 2λCaCH)
∫ 1
0
RCnC
]
+ (ρ∞C − ρC)
[
(λHaHC + λCaCH − 2λHaHC)
∫ 1
0
RHnH
]
−
(
a(t)
du2
dt
+ b(t)
du1
dt
)
(24)
where a and b are bounded functions defined by
a(t) := 2λH
1
(1 + αHu2)
2
∫ 1
0
mH(x)rH(x)(nH(t, x)− n∞H (x)) dx
+ 2λC
1
(1 + αCu2)
2
∫ 1
0
mC(x)rC(x)(nC(t, x)− n∞C (x)) dx,
b(t) := 2λH
∫ 1
0
mH(x)µH(x)(nH(t, x)− n∞H (x)) dx
+ 2λC
∫ 1
0
mC(x)µC(x)(nC(t, x)− n∞C (x)) dx.
The first two terms at the right-hand side of inequality (24) are equal to 0 thanks to the
choice made for (λH , λC) so that it simplifies to
dG
dt
> −
(
a(t)
du2
dt
+ b(t)
du1
dt
)
. (25)
Fifth step: conclusion.
Noting that dVdt 6
1
2G, it follows that V (t) − V (0) 6
1
2
∫ t
0 G(s) ds. From G(s) = G(t) −∫ t
s
dG
dt (z) dz, using (25) and by integrating the previous inequality, we have
V (t)− V (0)
t
6
1
2
G(t) +
1
2t
∫ t
0
∫ t
s
(
a(z)
du2
dt
(z) + b(z)
du1
dt
(z)
)
dz ds.
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Now, using the decomposition (21) introduced in the second step, we obtain:
2
V (t)− V (0)
t
− 1
t
∫ t
0
∫ t
s
(
a(z)
du2
dt
(z) + b(z)
du1
dt
(z)
)
dz ds− 2 (λHEH + λCEC)
6 −1
2
XTMX + 2
(
λHB̃H + λCB̃C
)
.
In other words, since the right-hand side of this inequality consists of nonpositive terms,
the claim on the convergence of ρH and ρC is proved if we establish that the left-hand side
tends to 0.
As a consequence of the estimate (23) on V established in the third step, 2
V (t)− V (0)
t
converges to 0. This is also true for 2 (λHEH + λCEC). It thus remains to analyse the
asymptotic behaviour of the function 1t
∫ t
0
∫ t
s
(
a(z)du2dt (z) + b(z)
du1
dt (z)
)
dz ds. The analysis
relies on the following lemma.
Lemma 2. Let φ in L∞(0,+∞), and u in BV ([0,+∞)). Then
lim
t→+∞
1
t
∫ t
0
∫ t
s
φ(z)u′(z) dz ds = 0.
Proof. Let us start by writing
1
t
∫ t
0
∫ t
s
φ(z)u′(z) dz ds =
1
t
∫ t
0
∫ t
0
φ(z)u′(z) dz ds− 1
t
∫ t
0
∫ s
0
φ(z)u′(z) dz ds
=
∫ t
0
φ(z)u′(z) dz − 1
t
∫ t
0
∫ s
0
φ(z)u′(z) dz ds
= Γ(t)− 1
t
∫ t
0
Γ(s) ds
where Γ(t) :=
∫ t
0 φ(z)u
′(z) dz. The expression above can thus be decomposed as the
function Γ minus its Cesàro average. To conclude, it suffices that Γ has a limit at +∞,
which in turn is true as soon as φu′ is integrable on the half-line. This fact is a direct
consequence of the boundedness of φ and the integrability of the derivative of a BV function
on [0,+∞).
This ends the proof of Theorem 1.
Remark 2. The situation differs from [34] where the non-local logistic term is of the
form
∫ 1
0 b(x, y)n(t, y) dy, with some strong competition assumption on the kernel b. In
particular, that assumption implies the uniqueness of the ESDs, which is not necessarily
true in our setting.
Remark 3. This theorem means that under general conditions, both populations concen-
trate and the total number of healthy (resp., cancer) cells converge. In the case of constant
controls and when there is selection of a unique phenotype in both populations, it provides
a complete understanding of the mapping
(ū1, ū2) 7−→ (x∞H , x∞C , ρ∞H , ρ∞C ), (26)
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where ρ∞H δx∞H and ρ
∞
C δx∞C are the respective limits of nH(t, ·) and nC(t, ·) inM
1(0, 1), as t
goes to +∞. In particular, if we restrict ourselves to constant controls and a large time T ,
the problem of minimising ρC(T ) is equivalent to minimising ρ∞C as a function of (ū1, ū2).
2.3 Speed of convergence in Theorem 1
Because it relies on a Lyapunov functional, Theorem 1 also yields results on the speeds of
convergence when the controls are constant, which we state and analyse separately in the
following corollary.
Corollary 1. Assume u1 ≡ ū1, u2 ≡ ū2.
Then, as t→ +∞, (ρH , ρC) = (ρ∞H , ρ∞C ) + O
((
ln(t)
t
) 1
2
)
and concentration occurs at speed
O
(
ln(t)
t
)
, in the following sense:
∫ 1
0
mH(x)RH (x, ρ
∞
H , ρ
∞
C , ū1, ū2)nH(t, x) dx = O
(
ln(t)
t
)
,∫ 1
0
mC(x)RC (x, ρ
∞
C , ρ
∞
H , ū1, ū2)nC(t, x) dx = O
(
ln(t)
t
)
.
In particular, if AH is reduced to a singleton x∞H , then
∀ε > 0,
∫
[0,1]\[x∞H−ε,x
∞
H+ε]
nH(t, x) dx = O
(
ln(t)
t
)
,
and similarly for AC .
Proof. The speed of convergence of (ρH , ρC) and of the integrals can be obtained by rewrit-
ing the end of the proof, namely that −12X
TMX + 2
(
λHB̃H + λCB̃C
)
is bounded from
below by 2V (t)−V (0)t , which converges to 0 as O
(
ln(t)
t
)
. Since each of those three terms is
nonpositive, they all converge to 0 at the previous speed, and the integrals of interest are
nothing but the functions B̃H and B̃C .
For the last statement, we fix ε > 0 and denote h := −mHRH (·, ρ∞H , ρ∞C , ū1, ū2) > 0 on
[0, 1], which by assumption vanishes at x∞H only. We choose a > 0 small enough such that
a1[0,1]\[x∞H−ε,x
∞
H+ε]
6 h on [0, 1]. This enables us to write∫
[0,1]\[x∞H−ε,x
∞
H+ε]
nH(t, x) dx 6
1
a
∫ 1
0
mH(x)RH (x, ρ
∞
H , ρ
∞
C , ū1, ū2)nH(t, x) dx = O
(
ln(t)
t
)
.
The reasoning is the same if AC is reduced to a singleton.
Remark 4. Although the Lyapunov functional gives us information on the speed of both
phenomena in the sense defined above, it does not say whether one of the two is faster.
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However, if AH or AC is reduced to a singleton, the speed O
(
ln(t)
t
)
obtained for the
convergence to 0 of the expression −12X
TMX + 2
(
λHB̃H + λCB̃C
)
is almost optimal:
there cannot exist any α > 1 such that this sum vanishes like O
(
1
tα
)
. This comes from
the fact that if it were to hold true, dVdt would be integrable on the half-line, which would
imply the convergence of V . This is not possible since either VH or VC goes to −∞.
2.4 Mathematical simulations of the effect of constant drug doses
Throughout the study, we will consider the following numerical data, taken from [45]:
rH(x) =
1.5
1 + x2
, rC(x) =
3
1 + x2
,
dH(x) =
1
2
(1− 0.1x), dC(x) =
1
2
(1− 0.3x),
aHH = 1, aCC = 1, aHC = 0.07, aCH = 0.01,
αH = 0.01, αC = 1,
umax1 = 3.5, u
max
2 = 7,
and the initial data
nH(0, x) = KH,0 exp(−(x− 0.5)2/ε), nC(0, x) = KC,0 exp(−(x− 0.5)2/ε),
with ε > 0 small (typically, we will take either ε = 0.1 or ε = 0.01), and where KH,0 > 0
and KC,0 > 0 are such that
ρH(0) = 2.7, ρC(0) = 0.5.
The value ρH(0) is not the same as in [45]: it is chosen to be slightly below the equilibrium
value of the system with nC ≡ 0, u1 ≡ 0, u2 ≡ 0, in accordance with the fact that there is
homeostasis in a healthy tissue. Indeed, we start with a non-negligible tumour which must
have (due to competition) slightly lowered the number of healthy cells with comparison to
a normal situation.
We also define ρCS(t) :=
∫ 1
0 (1− x)nC(t, x) dx, which may be seen as the total number at
time t of tumour cells that are sensitive, and ρCR(t) :=
∫ 1
0 xnC(t, x) dx, which may be seen
as the total number at time t of tumour cells that are resistant.
Of course, sensitivity/resistance being by construction a non-binary variable, the weights x
and 1−x are an example of a partition between a relatively sensitive class and a relatively
resistant class in the cancer cell population; other choices might be made for these weights,
e.g., x2 and 1− x2.
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Discussion of the choice for µH and µC . These functions measure the efficiency of
the drugs treatment. The choice done in [45] is
µH(x) =
0.2
0.72 + x2
, µC(x) =
0.4
0.72 + x2
.
However, with this choice of functions, if we take constant controls u1 and u2, with
u1(t) = Cst = u
max
1 = 3.5, u2(t) = Cst = 2,
then we can kill all tumour cells (at least, they decrease exponentially to 0), and no
optimisation is necessary. The results of a simulation can be seen on Figure 1.
Figure 1: Simulation with u1(t) = Cst = 3.5 and u2(t) = Cst = 2, in time T = 10. At
the top, left and middle: evolution in time of the curves x 7→ nH(t, x) and x 7→ nC(t, x),
with the initial conditions in black, and the final ones in red. At the right, top and
bottom: graphs of t 7→ ρC(t) and of t 7→ ρH(t). At the bottom, left and middle: graphs of
t 7→ ρH(t)ρH(t)+ρC(t) and of t 7→
ρCS(t)
ρC(t)
.
On Figure 1, the population of tumour cells is Gaussian-shaped, decreases exponentially
to 0 while its center is being shifted to the right: it means that tumour cells become
more and more resistant as time goes by. This is in agreement with the fact that cells
acquire resistance to treatment when drugs are given constantly. However, although the
proportion of sensitive cells t 7→ ρCS(t)ρC(t) is quickly decreasing, the drugs are still efficient
at killing the cells. This is not realistic, as it does not match the clinically observed
saturation phenomenon. Most cancer cells have acquired resistance and any immediate
further treatment should have no effect.
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In the simulation above, there is no saturation because the function µC is continuous and
positive over the whole interval [0, 1] and is not small enough close to 1. In order to model
this saturation phenomenon, we choose to modify the model used in [45], by modifying
slightly the function µC . The new function µC that will throughout be considered is defined
by
µC(x) = max
(
0.9
0.72 + 0.6x2
− 1, 0
)
.
On Figure 2, the former function µC is in blue, and the new one is in red.
Figure 2: Former function µC in blue, and new function µC in red.
This new function µC is nonnegative and decreasing on [0, 1], and vanishes identically on
a subinterval containing x = 1.
With this new function, the simulation of Figure 1, with u1 = Cst = 3.5 and u2 = Cst = 2,
is completely modified, as can be seen on Figure 3. Indeed, this time, the strategy consisting
of taking constant controls u1(t) = Cst = 3.5 and u2(t) = Cst = 2 is not efficient anymore
and does not allow for (almost) total eradication of the tumour. In sharp contrast, we
observe on Figure 1 that the tumour cells are growing again, moreover concentrating around
some resistant phenotype.
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Figure 3: Simulation with u1(t) = Cst = 3.5 and u2(t) = Cst = 2, in time T = 10, with
the new function µC .
Conclusion on constant controls. The simulations show that choosing constant doses
too high leads to the selection of resistant cells, and then, to regrowth of the cancer cell
population if these cells can become insensitive to the treatment. With the notations of
Theorem 1, it is because among constant controls, (umax1 , umax2 ) does not minimise ρ∞C .
However, it is quite clear that choosing the optimal constant dose (ū1, ū2) to minimise
ρ∞C leaves room for improvement, as the choice (u
max
1 , u
max
2 ) is still the optimal one for
sensitive cells. Therefore, it makes sense to allow u1 and u2 to be any functions satisfying
(4) as in (OCP), which we will study both from the theoretical and numerical points of
view in the next two sections.
3 Theoretical analysis of (OCP)
Before analysing (OCP), let us first consider a much simpler ODE model for which we
can find the solution explicitly in order to develop some intuition.
3.1 Simplified optimal control problems
We consider the ODE
dρ
dt
= (r − dρ(t)− µu(t))ρ(t),
ρ(0) = ρ0 > 0.
(27)
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(C1) Optimal control problem: minimise ρ(T ) over all possible solutions of (27) with a
L1-constraint on u, i.e., ∫ T
0
u(t) dt ≤ u1,max. (28)
Lemma 3. The optimal solution for problem (C1) is
uopt = u
1,maxδt=T .
Remark 5. The statement can be misleading: we actually prove that there is no optimal
solution, but rather that the problem leads to an infimum. Still, writing uopt = u1,maxδt=T
makes sense as a way to obtain the infimum is to take a family (uε)ε>0 in L1 which converges
to uopt, for example uε := 1εu
1,max1[T−ε,T ].
Adding another the constraint, we have a second optimal control problem
(C2) minimise ρ(T ) over all possible solutions of (27) with the L1-constraint (28) and a
L∞-constraint
u ≤ u∞,max. (29)
We assume u∞,maxT > u1,max, since otherwise it is clear that the optimal strategy is
u∞,max1[0,T ].
Lemma 4. We define T1(T ) := T − u
1,max
u∞,max . The optimal solution for problem (C2) is
uop = u
∞,max1[T1,T ]. (30)
The proofs of these two results can be found in Appendix B.
Remark 6. The previous lemmas on simplified equations give some insight on two impor-
tant features:
• for large times, constant controls lead to concentration, as evidenced by Theorem 1. As
explained more rigorously further below in Lemma 5, when the populations are concen-
trated on some single phenotypes, the integro-differential equations boil down to ODEs,
for which the last results and standard techniques from optimal control theory apply.
• for ODE models, it is optimal to use the maximal amount of drug at the end of the time-
window if there is a L1 constraint on the control. Avoiding the emergence of resistance will
indirectly act as some L1 constraint, which is why this result also provides some interesting
intuition on the optimal control problem (OCP).
3.2 Assumptions and further remarks
Let us start by mentioning a possible alternative state constraint for (OCP).
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Remark 7. Alternatively to (10), we might want to directly control the number of cancer
cells and replace (10) by
ρC(t) 6 C
max (31)
for some Cmax > 0. The set of constraints (10), (11) on the one hand, and (31), (11) on
the other hand, are similar. Although we focus on the first one in the sequel, our analysis
applies to the other set of constraints.
We now make several important additional assumptions which will be used throughout
this section, all relying on the notations of Theorem 1. Our first assumption is that
for any 0 6 ū1 6 umax1 , 0 6 ū2 6 u
max
2 , AH and AC are reduced to singletons. (32)
In this case, recall that Theorem 1 provides a mapping (ū1, ū2) 7→ (x∞H , x∞C , ρ∞H , ρ∞C ), and
with a slight abuse of notation, we will omit the dependence in (ū1, ū2) in the following
final assumptions:
whenever ū1, ū2 are admissible (i.e., such that neither the constraint (10) nor
the constraint (11) is violated), we require that the solution of the ODE system
dρH
dt
= RH (x
∞
H , ρH , ρC , u
max
1 , u
max
2 ) ρH ,
dρC
dt
= RC (x
∞
C , ρC , ρH , u
max
1 , u
max
2 ) ρC ,
(33)
with initial data (ρ∞C , ρ
∞
H ), has the following properties:
d
dt
ρC < 0,
d
dt
ρH < 0 and
d
dt
ρC
ρH
< 0. (34)
The assumption (34) means that both populations of cells decrease but that the treatment
is more efficient on cancer cells. In some sense, this is a curability assumption and it will
be crucial in the sequel.
We now motivate the choice of restricting our attention to the class BT by giving two
results.
3.3 Optimality of a concentrated initial population for a small time
Here, we assume that for any 0 6 ρC 6 ρmaxC , 0 6 ρH 6 ρ
max
H , 0 6 u1 6 u
max
1 and
0 6 u2 6 umax2 ,
x 7→ RC(x, ρC , ρH , u1, u2) has a unique minimum. (35)
For a given initial amount of cancer cells ρ0C > 0, we define:
Aρ0C
:=
{
n0C ∈M1(0, 1) such that
∫ 1
0
n0C(x) dx = ρ
0
C
}
.
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For n0C ∈ Aρ0C , and given n
0
H inM1(0, 1), final time tf > 0, and controls u1, u2 in BV (0, tf )
satisfying (3), we consider the associated trajectory (nH(·, x), nC(·, x)) on [0, tf ] solution
to the system (4) starting from (n0H , n
0
C).
We consider the following minimisation problem
inf
06u1(t)6umax1
06u2(t)6umax2
inf
n0C∈AρC0
ρC(tf ). (36)
In other words, for a fixed initial tumour size, we aim at tackling the following question:
what is the cancer cells’ best possible repartition in phenotype?
A simpler (and instantaneous) version of the previous optimisation problem for tf small is
inf
06u16umax1
06u26umax2
inf
n0C∈AρC0
dρC
dt
(0), (37)
for which the solution is easily obtained, and given in the following proposition.
Proposition 1. Let g := RC
(
·, ρ0C , ρ0H , umax1 , umax2
)
. We define xC by {xC} := arg min g
and ñ0C := ρ
0
CδxC . The optimal solution for the optimisation problem (37) is given by(
umax1 , u
max
2 , ρ
0
CδxC
)
. (38)
Proof. For any 0 6 u1 6 umax1 , 0 6 u2 6 umax2 , n0C ∈ AρC0 ,
dρC
dt
(0) =
∫ 1
0
RC
(
x, ρ0C , ρ
0
H , u1, u2
)
n0C(x) dx >
∫ 1
0
g(x)n0C(x) dx
with equality if and only if u1 = umax1 , u2 = umax2 .
We also have
∫ 1
0 g(x)n
0
C(x) dx >
∫ 1
0 g(xC)n
0
C(x) dx = g(xC)ρ
0
C and it remains to prove
that there is equality if and only if n0C = ρ
0
CδxC . If n
0
C 6= ρ0CδxC there exists a ∈ supp
(
n0C
)
,
a 6= xC : it is therefore possible to find ε > 0 such that both xC 6∈ [a − ε, a + ε] and∫
[a−ε,a+ε] n
0
C(x) dx > 0.
This implies∫ 1
0
(g(x)− g(xC))n0C(x) dx >
∫
[a−ε,a+ε]
(g(x)− g(xC))n0C(x) dx > 0,
which concludes the proof.
For (OCP), the previous Proposition means that, very close to T , the best shape of the
cancer cell density nC(t, ·) is a Dirac mass. As it was proved in Theorem 1, it is possible
(in arbitrarily large time) to reach Dirac masses with constant controls. The combination
of these two results is our motivation for the restriction to the set BT .
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3.4 Reduction of IDEs to ODEs at the end of the long first phase
Because of the previous result, it makes sense to steer the cancer dell density as close as
possible to a Dirac mass. As it was proved in Theorem 1, it is possible (in large time
limit) to reach Dirac masses with constant controls. Our aim is now to prove that if we
give constant controls (ū1, ū2) for a long time, the dynamics of the total number of cells
(ρH , ρC) are arbitrarily close to being driven by a system of ODEs, a result which comes
from the concentration of the IDE on (x∞H , x
∞
C ). The rigorous statement is given hereafter:
Lemma 5. We fix T2 > 0, 0 6 ū1 6 umax1 and 0 6 ū2 6 u
max
2 . We consider any controls
(u1, u2) defined on [0, T1 +T2] as follows: they are constant equal to (ū1, ū2) on [0, T1], and
any BV functions on [T1, T1 +T2] which satisfy (3). Let (nH , nC) be the solution of (4) on
[0, T1 + T2], with corresponding (ρH , ρC).
Then
lim
T1→+∞
sup
[T1,T1+T2]
max (|ρH − ρ̃H |, |ρC − ρ̃C |) = 0,
where (ρ̃H , ρ̃C) solves the controlled ODE system
dρ̃H
dt
= RH (x
∞
H , ρ̃H , ρ̃C , u1, u2) ρ̃H ,
dρ̃C
dt
= RC (x
∞
C , ρ̃C , ρ̃H , u1, u2) ρ̃C ,
(39)
defined on [T1, T1 + T2], starting at T1 from (ρH(T1), ρC(T1)).
Proof. Let ε > 0. We focus on the equation on nH which we integrate in x for any
t ∈ [T1, T1 + T2]:
dρH
dt
=
∫ 1
0
RH(x, ρH , ρC , u1, u2)nH(t, x) dx
= RH (x
∞
H , ρH , ρC , u1, u2) ρH
+
∫ 1
0
(RH(x, ρH , ρC , u1, u2)−RH (x∞H , ρH , ρC , u1, u2))nH(t, x) dx
For the first term, we write
RH(x
∞
H , ρH , ρC , u1, u2)ρH = RH(x
∞
H , ρH , ρC , u1, u2)ρ̃H +RH(x
∞
H , ρH , ρC , u1, u2)(ρH − ρ̃H)
=
dρ̃H
dt
+ ρ̃HdH(x
∞
H ) (−aHH(ρH − ρ̃H)− aHC(ρC − ρ̃C))
+RH (x
∞
H , ρH , ρC , u1, u2) (ρH − ρ̃H)
This means we end up with
d
dt
(ρH − ρ̃H) = ρ̃HdH(x∞H ) (−aHH(ρH − ρ̃H)− aHC(ρC − ρ̃C))
+RH (x
∞
H , ρH , ρC , u1, u2) (ρH − ρ̃H)
+
∫ 1
0
(RH(x, ρH , ρC , u1, u2)−RH (x∞H , ρH , ρC , u1, u2))nH(t, x) dx.
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We look at the last term separately: the first two ones are linked to the discrepancy between
ρ and ρ̃, while the last one will be small because nH is concentrated if T1 is large enough.
Setting w := max (|ρH − ρ̃H |, |ρC − ρ̃C |), we have the differential inequality
d
dt
|ρH − ρ̃H | 6 Cw +
∫ 1
0
(RH(x, ρH , ρC , u1, u2)−RH (x∞H , ρH , ρC , u1, u2))nH(t, x) dx
(40)
for some constant C > 0. The last term can be decomposed as
1
1 + αHu2
∫ 1
0
(rH(x)− rH(x∞H ))nH(t, x) dx
− u1
∫ 1
0
(µH(x)− µH(x∞H ))nH(t, x) dx− IH
∫ 1
0
(dH(x)− dH(x∞H ))nH(t, x) dx.
Note that u1, 11+αHu2 and IH are all bounded on [T1, T1 + T2]. Thus, if for any generic
function φ,
∫ 1
0 (φH(x)− φH(x
∞
H ))nH(t, x) dx is arbitrarily small, so is the last quantity.
To that end, we write the solution of the IDE in exponential form
nH(t, x) = nH(T1, x) exp
(∫ t
T1
RH (x, ρH(s), ρC(s), u1(s), u2(s)) ds
)
,
where the exponential is uniformly bounded on [0, 1] × [T1, T1 + T2], which means that∣∣∣∫ 10 (φH(x)− φH(x∞H ))nH(t, x) dx∣∣∣ 6 C ∫ 10 |φH(x)− φH(x∞H )|nH(T1, x) dx. Since
nH(T1, ·) converges to ρ∞H δx∞H in M
1(0, 1) as T1 goes to +∞, this quantity is arbitrarily
small. Plugging this estimate into (40) and writing a similar inequality for the equations
on the cancer cells, we obtain for T1 large enough dwdt 6 Cw+ ε. We conclude by applying
the Gronwall lemma, together with the fact that w(T1) = 0.
3.5 Analysis of the second phase
According to the previous results, for large T and admissible constant controls (ū1, ū2),
we arrive at concentrated populations whose dynamics are driven by a system of ODEs.
This naturally leads to considering the following optimal control problem, on the resulting
ODE concentrated in (x∞H , x
∞
C ), starting from (ρ
∞
H , ρ
∞
C ) at t = 0. For readability, we write
gH for gH(x∞H ) (resp., gC for g(x
∞
C )) for any function gH (resp., gC), and we stress that all
assumptions made in this subsection are made for all possible admissible constant controls
(ū1, ū2).
The ODE system of equations now reads
dρH
dt
=
(
rH
1 + αHu2
− dHIH − u1µH︸ ︷︷ ︸
RH
)
ρH ,
dρC
dt
=
(
rC
1 + αCu2
− dCIC − u1µC︸ ︷︷ ︸
RC
)
ρC .
(41)
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For a given TM2 > 0, we investigate the optimal problem of minimising ρC(tf ) for tf 6 TM2
and controls (u1, u2) which satisfy (3), as well as the constraints (11) and (10). The
constraint (10) rewrites ρCρH 6 γ with
γ :=
1− θHC
θHC
.
Assume that there exists an optimal solution which is the concatenation of free and con-
strained arcs (either on the constraint (11) or (10)), with associated times (ti)16i6M . In
particular, we thus assume without loss of generality that the parameters are such that
both constraints do not saturate simultaneously on an optimal arc. (42)
Then, by the Pontryagin maximum principle for an optimal control problem with state
constraints (see [71]), there exists a bounded variation adjoint vector p = (pH , pC) defined
on [0, tf ], a scalar p0 6 0, non-negative functions η1 and η2 and non-negative scalars νi,
i = 1, . . . ,M such that if we define the Hamiltonian function by
H(ρH , ρC , pH , pC , u1, u2)
:= pHRHρH + pCRCρC + η1(θHρ
0
H − ρH) + η2(ρC − γρH)
= − pHdHIHρH − pCdCICρC +
(
rHpHρH
1 + αHu2
+
rCpCρC
1 + αCu2
)
− (µHpHρH + µCpCρC)u1 + η1(θHρ0H − ρH) + η2(ρC − γρH),
we have
1. p, p0, η1, η2 and the (νi)i=1,...,M are not all zero.
2. The adjoint vector satisfies
dpH
dt
= − ∂H
∂ρH
= −pH (−aHHdHρH +RH) + aCHdCpCρC + η1 + γη2,
dpC
dt
= − ∂H
∂ρC
= −pC (−aCCdCρC +RC) + aHCdHpHρH − η2,
(43)
with pH(tf ) = 0, pC(tf ) = p0.
3. t 7−→ η1(t) (resp. t 7−→ η2(t)) is continuous along (11) (resp. (10)), and is such that
η1(θHρ
0
H − ρH) = 0 (resp. η2(ρC − γρH) = 0) on [0, tf ].
4. For any i = 1, . . . ,M , the Hamiltonian is continuous at ti. If ti is a junction or contact2
point with the boundary (11) (resp. with the boundary (10)), pH(t+i ) = pH(t
−
i ) + νi,
pC(t
+
i ) = pC(t
−
i ) (resp. pH(t
+
i ) = pH(t
−
i ) + γνi, pC(t
+
i ) = pC(t
−
i )− νi).
5. The controls u1, u2 maximise the Hamiltonian almost everywhere.
2The starting and ending points of a boundary arc are called junction points if they are distinct, and
contact points if they coincide (i.e., if the arc is reduced to a singleton).
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We now make several technical assumptions (for all admissible constant controls (ū1, ū2))
by requiring
γ <
µH
µC
µCaHHdH − µHaCHdC
µHaCCdC − µCaHCdH
(44)
(assuming first µCaHHdH > µHaCHdC , aCCµHdC > aHCµCdH),
µH , µC > 0, (45)
αHµCrH < αCµHrC , αHµHrC < αCµCrH (46)
(αCrHµC − αHrCµH) (umax2 )
2 + 2(rHµC − rCµH)umax2 +
αHrHµC − αCrCµH
αHαC
< 0. (47)
Note that the two last assumptions are satisfied as soon as αHαC is very small, at least
compared to µHµC . This amounts to saying that cytostatic drugs specifically target the
cancer cells better than cytotoxic drugs do.
This last necessary condition motivates the definitions
φ1 := µHpHρH + µCpCρC ,
and (abusively, since this quantity also depends on t)
ψ(u2) :=
rHpHρH
1 + αHu2
+
rCpCρC
1 + αCu2
.
Let us first analyse a constrained arc on (11), whenever it is not reduced to a singleton.
Arc on the constraint (11).
First note that ρC = ρCρH ρH =
ρC
ρH
θHρ
0
H is bounded from above by γ θHρ
0
H . If we differen-
tiate the constraint, we find that u1 and u2 are determined by
rH
1 + αHu2
− dH(aHHθHρ0H + aHCρC)− u1µH = 0, (48)
together with the fact that
(u1, u2) ∈ arg max
(
rHpHρH
1 + αHu2
+
rCpCρC
1 + αCu2
− (µHpHρH + µCpCρC)u1
)
= arg max
pCρC
µH
(
rCµH
1 + αCu2
− rHµC
1 + αHu2
)
One can check that (46) and (47) are sufficient conditions to have decrease of the function
u2 7→ rCµH1+αCu2 −
rHµC
1+αHu2
. In particular, u2 = umax2 if pC < 0, u2 = 0 if pC > 0. Thus, the
maximisation condition is equivalent to maximising −φ1u1 if pC does not vanish on the
arc. Hence, φ1 = 0 when this condition on pC is fulfilled. We also obtain u1 in feedback
form along the arc, and when pC does not vanish it is given by:
ub,v1 :=
1
µH
(
rH
1 + αHv
− dH(aHHθHρ0H + aHCρC)
)
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where v = 0 or v = umax2 depending on the sign of pC . We assume that this is an admissible
control, i.e., that it satisfies
0 < ub,v1 < u
max
1 (49)
for v = 0 and v = umax2 , and any 0 6 ρC 6 γθHρ0H . If pC > 0 and u2 = 0, the dynamics
of ρC on the arc (11) are given by
dρC
dt
=
1
µH
(rb − dbρC) ρC (50)
with
rd := (rCµH − rHµC) + (aHHdHµC − µHaCHdC) θHρ0H , db := (aCCµHdC − aHCµCdH) ,
which we assume to be positive. This autonomous ODE leads to a monotonic behaviour
of ρC . In order to ensure that the boundary control u1 = u
b,0
1 is not enough to prevent the
increase of ρC we assume the following
γ θHρ
0
H <
rd
bd
. (51)
The previous hypothesis implies that ρC will increase on an arc on (11) when pC > 0.
Arc on the constraint (10).
If we differentiate the constraint, we find that RH = RC , i.e., u1 and u2 are related to one
another by
rH
1 + αHu2
− dHρH(aHH + γaHC)− u1µH =
rC
1 + αCu2
− dCρH(γaCC + aCH)− u1µC .
We are now set to prove the result:
Proposition 2. Assume (8), (32), (34), (42), (44), (45), (46), (47), (49), (51) and that
there exists an optimal solution which is the concatenation of free and constrained arcs
(either on the constraint (11) or (10)), with associated times (ti)16i6M .
Then, the last three possible arcs are:
• a boundary arc along the constraint (10).
• a free arc with controls u1 = umax1 and u2 = umax2 ,
• a boundary arc along the constraint (11) with u2 = umax2 .
The proof is technical and can be found in Appendix C.
3.6 Solution of (OCP) in BT for large T : proof of Theorem 2
Recall that we want to solve (OCP) for controls (u1, u2) ∈ BT for large T and small TM2 ,
a choice motivated by the previous results. For a given T , we denote
(
ū
(T )
1 , ū
(T )
2
)
a choice
of optimal values for the constant controls during the first phase.
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Theorem 2. Assume the hypotheses of Proposition 2. Then asymptotically in T and for
TM2 small, there exists at least one solution to (OCP) in BT . More precisely, there exists(
ūopt1 , ū
opt
2 , T
ode
2
)
,
(
uode1 , u
ode
2
)
∈ BV
(
0, T ode2
)
such that if we define the control (u1, u2) by
(u1, u2)(t) =
{ (
ūopt1 , ū
opt
2
)
on
(
0, T − T ode2
)
,(
uode1 (t− T + T ode2 ), uode2 (t− T + T ode2 )
)
on
(
T − T ode2 , T
)
then up to a subsequence we have
lim
T→+∞
(
CT (u1, u2)− inf
(u1,u2)∈BT
CT (u1, u2)
)
= 0,
meaning that (u1, u2) is quasi-optimal if T is large enough. Furthermore, on
(
T − T ode2 , T
)
the optimal trajectory trajectory obtained with (u1, u2) is the concatenation of at most three
arcs:
• a quasi-boundary arc along the constraint (10),
• a free arc with controls u1 = umax1 and u2 = umax2 ,
• a quasi-boundary arc along the constraint (11), with u2 = umax2 .
Remark 8. By quasi-boundary arc, we mean that the quasi-optimal control is such that
(ρH , ρC) almost saturates the constraints, i.e., up to an error vanishing as T goes to +∞.
Proof.
Up to a subsequence, still denoted T , we can find
(
ūopt1 , ū
opt
2
)
such that
(
ū
(T )
1 , ū
(T )
2
)
con-
verges to
(
ūopt1 , ū
opt
2
)
as T → +∞. These values for the constant controls yield asymptotic
phenotypes
(
xoptH , x
opt
C
)
thanks to Theorem 1. Then, for any choice of time T2 6 TM2 and
BV controls (u1, u2) on (T − T2, T ),
lim
T→+∞
sup
[T−T2,T ]
max (|ρH − ρ̃H |, |ρC − ρ̃C |) = 0, (52)
with the notations of Lemma 5: ρ is obtained from the IDE system, while ρ̃ is obtained
from the ODE concentrated on
(
xoptH , x
opt
C
)
. This is a consequence of a slight refinement
of Lemma 5. Indeed, for T large, the IDE is almost concentrated on some
(
x
(T )
H , x
(T )
C
)
associated to
(
ū
(T )
1 , ū
(T )
2
)
. The formulae for these quantities given by Theorem 1 show that(
x
(T )
H , x
(T )
C
)
converges to
(
xoptH , x
opt
C
)
, hence the concentration of the IDE on
(
xoptH , x
opt
C
)
and the result (52).
As a consequence, the optimal strategy for the ODE, obtained by Proposition 2 is also
optimal for the IDE, up to an error vanishing as T goes to infinity. We denote T ode2 6 TM2 ,(
uode1 , u
ode
2
)
∈ BV
(
0, T ode2
)
the solutions of this optimal control problem. The last state-
ments of the theorem are then a direct consequence of Proposition 2 and the assumption
that TM2 is small, since the IDE and ODE trajectories are arbitrarily close.
30
4 Numerical simulations
In this section, we solve (OCP) numerically in the full class AT . We will compare the
results with the previous section, and check that alternative strategies to the one given in
Theorem 2 are indeed sub-optimal when T is large.
4.1 Numerical simulations of the solution to (OCP)
For a survey on numerical methods in optimal control of ODEs, we refer to [69].
Here, we use direct methods which consist in discretising the whole problem and reducing
it to a "standard" constrained optimisation problem. The IDE structure is dealt with a
discretisation in phenotype, which adds to the discretisation in time. The dimension of the
resulting optimisation problem becomes larger as the discretisation becomes finer. This
method is hence computationally demanding and its numerical implementation requires
some care. It relies on combining automatic differentiation and the modelling language
AMPL (see [24]) with the expert optimisation routine IpOpt (see [72]). Several different
numerical tricks (hot start, numerical refinement, etc) were also needed.
For the simulations, we take θHC = 0.4, θH = 0.6, ε = 0.1. We let T take the values
T = 30 and T = 60. The results are reported on Figures 4 and 5 respectively.
Figure 4: Simulation of (OCP) for T = 30.
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Figure 5: Simulation of (OCP) for T = 60.
These simulations clearly indicate that for the chosen numerical data, if T is large enough,
then the optimal controls are such that:
• the optimal control u1 is first equal to 0 on a long arc. Then, on a short-time arc,
u1 = u
max
1 and then to a value such that the constraint (11) saturates;
• the optimal control u2 has a three-part structure, with a long-time starting arc which
is a boundary arc, that is, an arc along which the state constraint (10) is (very quickly)
saturated. It corresponds to an almost constant value for the control u2. The last
short-time arc coincides with that of u1, and along this arc u2 = umax2 .
We denote by ts(T ) the switching time, defined by largest time such that u1(t) = 0 for all
t < ts(T ).
According to the numerical simulations, as T tends to +∞, both x 7→ nC(ts(T ), x), x 7→
nH(ts(T ), x) converge to (weighted) Dirac masses. Since the controls u1 and u2 are almost
constant on (0, ts(T )), this is in accordance with Theorem 1. The cancer cell population
is then concentrated on a phenotype on which the drugs are very efficient.
More precisely, as T tends to +∞, the optimal strategy seems tends to a two-piece trajec-
tory, consisting of:
• a first long-time arc, along the boundary ρH(t)ρH(t)+ρC(t) = δCH , with u1(t) = 0 and with
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a constant control u2, at the end of which the populations of healthy and of cancer
cells have concentrated on some given sensitive phenotype;
• a second short-time arc along which the populations of healthy and cancer cells are
very quickly decreasing.
We also find that the mapping T 7−→ ρC(T ) (where ρC(T ) is the value obtained by solving
(OCP) on [0, T ]) is decreasing. This is because our parameters are such that, once concen-
trated on a sensitive phenotype, the cancer cell population satisfies a controlled ODE for
which there exists a strategy letting ρC converge to 0. Because our model is exponential,
we cannot reach 0 exactly but for very small values of ρC , one can consider that the tumour
has been eradicated.
Remark 9. In order to avoid additional lengthy hypotheses, we did not give conditions
under which the strategy established in Theorem 2 can further be identified. However, the
numerical solutions show that, for generic parameters, it can be expected that:
• the constant controls on the first phase are such that at the end of the first phase, we
have saturation of (10),
• the second phase is of time duration TM2 and starts with a constrained arc along (10).
4.2 Comparison with clinical settings
As explained before, our results advocate for a first long phase which must be all the
more long for an initially heterogeneous tumour (with respect to resistance). They also
apply to ’born to be bad’ tumours [64], with high initial heterogeneity with respect to
genes or phenotypes in general. Indeed, the heterogeneity or homogeneity we address
here is related to one phenotype defined by resistance towards one category of cytotoxic
drug. In this sense, our use of the term heterogeneity is unambiguous, functionally defined,
and cannot be superimposed on other more classical uses, defined by the accumulation of
mutations, such as in [23, 25, 64].
This being said, we are ultimately concerned with the application of our optimal control
methods to the improvement of classical therapeutic regimens in which repeated courses
of chemotherapy are delivered to patients with cancer. To this end, we keep the previous
parameters, that are in particular relevant to represent an initially heterogeneous tumour,
and we propose for possible implementation in the clinic a quasi-periodic strategy such as
in the example defined below:
• As long as ρHρH+ρC > θHC , we follow the drug-holiday strategy by choosing u1 = ū1 =
0, u2 = ū2 = 0.5 obtained in the previous numerical simulations.
• Then, as long as ρH > θHρH(0), we use the maximal amount of drugs. As soon as
ρH = θHρH(0), go back to the drug-holiday strategy.
The implementation is straightforward, Figure 6 shows an example for T = 60. This
strategy allows to maintain the tumour size below some upper value and to prevent resistant
33
cells from taking over the whole population. However, the tumour is not eradicated and
this strategy is far from being optimal: ρC(T ) is slightly below 1, to be compared to the
value obtained with T = 60 (see Figure5) with the optimal strategy, which is around
1.10−5. It is another proof of the importance of a long first phase. It also shows that,
at least with our parameters, the last arc on the constraint (11) obtained in the previous
simulations is instrumental in view of significantly decreasing the tumour size.
Figure 6: Quasi-periodic strategy, for T = 60.
To assess the importance of the saturation of the constraint ρH = θHρH(0), we complement
the previous strategy with an arc on this constraint, with u2 = umax2 , and adequately chosen
feedback control u1 obtained from the equality dρHdt = 0. We go back to the drug-holiday
strategy as soon as ρC starts increasing again, since it is a sign that the tumour has become
too resistant. We choose T = 100 to have enough cycles; the corresponding results are
reported on Figure 7 below. They tend to show that ρC can be brought arbitrarily close to
0 after enough cycles, meaning that there is a chance for total eradication of the tumour.
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Figure 7: Second quasi-periodic strategy, for T = 100.
5 Conclusion
5.1 Summary of the results
By analysing a controlled integro-differential system of cancer and healthy cells structured
by a resistance phenotype, we have mathematically investigated the effect of combined
chemotherapeutic (cytotoxic and cytostatic) drugs on a tumour. Since we chose a biologi-
cally grounded modelling for the resistance phenomenon and took the healthy tissue into
account, our approach is tailored for understanding and circumventing the two main pit-
falls in cancer therapy: resistance to drugs and toxicity to healthy tissue. The goal of our
analysis was indeed twofold: check that our model can reproduce the possible deleterious
effect of chemotherapy when MTDs are used (the standard clinical strategy), and propose
alternative (optimised) infusion protocols.
Since MTD can first strongly reduce the size of the tumour which then starts growing
again, we addressed the first question through an asymptotic analysis of the model. This
was performed in Theorem 1, which showed that both populations converge, while the
cells concentrate on some phenotypes. This theorem extends results that so far were
established only in the case of a single integro-differential equation, although the ideas
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are radically different because the usual technique (integration w.r.t. the phenotype to
show convergence, and then relying on the exponential nature of convergence, to show
concentration) does not work in our context. The proof of convergence and concentration,
presented in Section 2, relies instead on a suitably defined Lyapunov function, whose
analysis gives the speed of convergence and concentration. Interestingly, the approach
could incorporate controls which are not only constant, but also asymptotically constant.
The rest of the article was then devoted to addressing the second question, by considering
the optimal control problem (OCP) of minimising the number of cancer cells on a given
time interval [0, T ], keeping the tumour size in check and limiting damage to the healthy
tissue. In Section 3, we gave several rigorous mathematical arguments to explain why, when
T is large, a good strategy is to first steer the cancer cell population on an appropriate
phenotype by first giving constant doses for a long time. These arguments justified a
restriction to a smaller class of controls for which we managed to identify an asymptotically
optimal strategy in large time, presented in Theorem 2.
In Section 4, we showed through numerical simulations that, when T increases, the optimal
solution is indeed increasingly close to a two-phase trajectory. The first very long phase
consists in giving low doses of drugs in order to let the cancer cell population concentrate on
a given sensitive phenotype. The doses are chosen as low as the constraint on the relative
tumour size allows it. Our results advocate for a first long phase which must be all the
more long for an initially heterogeneous tumour (with respect to resistance). During the
second phase, we numerically recover the expected trajectory, given by Theorem 2: high
doses are given (MTD as long as the constraint on the healthy tissue does not saturate)
and the cancer cell population quickly decreases.
5.2 Possible generalisations
We have focused on a 1 dimensional phenotype x ∈ [0, 1]. In applications, however, it might
be suitable to consider multi-dimensional phenotypes in order to account for the complexity
of resistance. This is for example what is done in [15] where the relevant phenotype is 2
dimensional and decided to be the combination of proliferation and survival potentials.
With some technical adaptations, the results established in this paper generalise to any
compact subset of Rd, d > 1. For the application one would need to specify how the
functions depend (monotonically or not) on the various components of the phenotype.
A possible generalisation for our model is to take into account the fact that cells can
change phenotype, for instance through (random) genetic mutations, i.e., modifications
of the DNA. These are irreversible and are passed from one cell to its daughter cells
through division. However, it is now widely believed that such mutations are very rare
with respect to the typical timescales that are of medical interest (which in the case of
drug resistance phenomena are much shorter than the timescale of a human life, a time
during which mutations certainly exist and can explain the development of diseases, see,
e.g. [31] about acute myeloid leukaemia), and thus they can be disregarded at least as a first
approximation. In contrast, epimutations (i.e., mechanisms which alter gene expression
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but not the DNA sequence base pairs themselves) are thought to be much more frequent [9,
62, 73].
If epimutations are exclusively random, they can be modelled by a diffusion term, in which
case (4) would be modified as follows:
∂nH
∂t
(t, x) = RH (x, ρH(t), ρC(t), u1(t), u2(t))nH(t, x) + βH
∂2nH
∂x2
(t, x),
∂nC
∂t
(t, x) = RC (x, ρC(t), ρH(t), u1(t), u2(t))nC(t, x) + βC
∂2nC
∂x2
(t, x),
(53)
together with Neumann boudary conditions in x = 0 and x = 1. Here, βH and βC stand
for the random epimutations rates of the healthy and cancer cell populations, respectively.
The Darwinian idea that the fittest individuals are selected exclusively because of random
events affecting the genome or its expression has been recently challenged as observations
on genomic evolution cannot be accounted for by sheer Darwinian mechanisms [42], maybe
also as ideas from Lamarck are regaining popularity. Such theories advocate the existence
of adaptive behaviours: individuals actively adapt to their environment, seeking for phe-
notype changes that make them fitter. These can be seen as stress-induced epimutations
and can be mathematically modelled by an advection term, as in [15, 43]. This would lead
to a model of the form
∂nH
∂t
(t, x) +
∂
∂x
(vH (x, u1(t), u2(t))nH(t, x))
= RH (x, ρH(t), ρC(t), u1(t), u2(t))nH(t, x) + βH
∂2nH
∂x2
(t, x),
∂nC
∂t
(t, x) +
∂
∂x
(vC (x, u1(t), u2(t))nC(t, x))
= RC (x, ρC(t), ρH(t), u1(t), u2(t))nC(t, x) + βC
∂2nC
∂x2
(t, x),
(54)
together with Neumann boudary conditions in x = 0 and x = 1. Here, vH and vC are
the velocities with which healthy and cancer cells adapt to their environment, respectively,
which are assumed to vanish in x = 0 and x = 1. Because we assume that the adaptation
of cells is induced by the stress created by the drugs, vH and vC depend on u1 and u2.
Another extension could involve a mixed deterministic/stochastic framework, namely using
a piecewise deterministic Markov process (PDMP [19], see [55] for the optimal control of
this class of equations). In these models, mutations are stochastic jumps between deter-
ministic (and phenotypically reversible) models, each jump becoming less and less rare in
the course of phenotypic evolution in the deterministic processes. Furthermore, in these
models, the probability of jump would depend exclusively on (and as an increasing function
of) the phenotype structure variable, that would thus bear a quantitative meaning of ma-
lignancy, or phenotype plasticity entraining genetic instability (this last point is discussed
with references in [14]).
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A final extension should stem from the fact that tumours are also very heterogeneous in
space (for example, because cells at the outer rim and cells at the centre of a tumour
spheroid encompass very different metabolic conditions; more genenerally, high hetero-
geneity depending on space has been experimentally shown in solid tumours [25, 64], which
should lead to also structure the populations of cells according to an added space variable.
Another modelling advantage of such representation is that the interaction between the
tumour and the healthy tissue is itself spatial, since part of it essentially happens at the
boundary of the tumour, through direct contact. For possible cancer models taking both
phenotype and space into account, we refer to [35, 44, 48].
5.3 Open problems
Asymptotic analysis. In this paper, we have extended well-known results for a single
IDE to systems of IDEs. However, in applications it could be interesting to consider the
case of general competitive of the form
∂nH
∂t
(t, x) = RH (x, ρH , ρC)nH(t, x),
∂nC
∂t
(t, x) = RC (x, ρC , ρH)nC(t, x), (55)
with RH decreasing in ρC , RC decreasing with ρH . Proving convergence and concentration
for such systems is completely open. Indeed, our Lyapunov function is specifically suited to
the specific linear setting of the model (4): it cannot be applied to any general competitive
system. Note that some numerical simulations indicate that no oscillations occur, which
may mean that ρH and ρC converge.
Similarly, characterising the asymptotic behaviour of PDE systems like (53) and (54) (even
without the control terms) is an interesting and open problem, even for a single equation.
Let us mention that when the rate of mutations is small, much can be found in the literature
on the asymptotics of these models when this small parameter goes to 0, after a proper
rescaling of time [4, 46]. If this parameter is fixed, classical asymptotics for t going to
infinity have up to our knowledge not been carried out.
Optimal control. In order to try and solve the optimal control problem (OCP), we had
to treat the question of the optimal control of IDEs. Although a PMP exists for such
equations, we took another path because the resulting equations were too intricate.
A key idea to justify the restriction to a class of controls which are first constant on a
long phase is to prove that the tumour (among all possible tumours of given size) which
can be treated the most efficiently is homogeneous in phenotype, i.e., a Dirac mass in
mathematical terms: the first long phase then aims at approaching this ’ideal’ situation
to start the second phase. We established the optimality of Dirac masses for a short time,
but not for any time.
If we want to analyse similar optimal control problems for (53) or (54), we shall have
to deal with optimal control of PDEs for which techniques are very different [16, 70]. A
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first approach would be to focus on (53), and see whether and how the optimal controls
converge to the ones obtained in this paper as the rates of epimutations go to 0.
A Proof of Lemma 1
Proof. We are going to prove that ρC is a BV function. To that end, let us prove that ρC
is bounded from above, and that it has integrable negative part.
First step: upper bound for ρC .
The existence of such a bound comes from integrating the equation with respect to x:
ρ′C(t) =
∫ 1
0
RC (x, ρC , 0ū1, ū2)nC(t, x) dx.
If ρC is too large, the right hand side is negative, forcing ρC to decrease. It proves the
claim on the upper bound for ρC .
Similarly, because of assumption (14), ρC increases if ρC is too close to 0: ρC is bounded
from below by some ρminC > 0.
Second step: estimate on the negative part of ρC .
We define qC :=
dρC
dt
and wish to prove that (qC)− ∈ L1(0,+∞). We differentiate
dρC
dt
=∫ 1
0 nCRC to obtain:
dqC
dt
=
∫ 1
0
nCR
2
C +
(∫ 1
0
nC
∂RC
∂ρC
)
qC
It provides an upper bound for the negative part of qC :
d(qC)−
dt
6
(∫ 1
0
nC
∂RC
∂ρC
)
(qC)− 6 −aCCdminC ρminC (qC)−
where 0 < dminC 6 dC on [0, 1]. We conclude that the negative part of qC vanishes expo-
nentially (and consequently, is integrable over the half-line). Therefore, ρC converges to
some ρ∞C > 0.
Third step: identification of ρ∞C .
Now, we have
nC(t, x) = n
0
C(x) exp
((
rC(x)
1 + αC ū2
− ū1µC(x)
)
t− dC(x)aCC
∫ t
0
ρC(s) ds
)
For large t, we have
∫ t
0 ρC(s) ds ∼ ρ
∞
C t and hence the asymptotic behaviour depends on
the function bC defined on [0, 1] by
bC(x) =
rC(x)
1 + αC ū2
− ū1µC(x)− dC(x)aCCρ∞C .
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Let BC ⊂ [0, 1] be the set of points at which the function bC reaches its maximum.
Let us prove that bC(x) = 0, for every x ∈ BC . We argue by contradiction. If bC(x) > 0 for
some x ∈ BC , then there exists a nontrivial interval I ⊂ [0, 1] along which bC is positive,
and therefore nC(t, ·) takes larger and larger values along I as t increases. This contradicts
the fact that ρC(t) converges to ρ∞C . Similarly, if bC < 0 globally, ρC converges to 0, a
contradiction.
The function bC is thus nonpositive on [0, 1], and vanishes at any point of BC . The lemma
follows easily.
B Proofs for the simplified optimal control problems
B.1 Proof of Lemma 3
Proof. Using the family uε defined in Remark 5, we obtain the corresponding ρε(T ), which
can be computed exactly, as well as its limit. It is given by
ρopt(T ) := ρopt(T
−) exp(−µu1,max)
where ρopt is the function obtained through ddtρopt(t) = (r− dρopt(t))ρopt(t) for t < T , and
ρopt(0) = ρ0.
Now, let any u satisfy (28). The solution of (27) with u is thus a subsolution of that
satisfied by ρopt, leading to ρ 6 ρopt on [0, T ). Using u > 0, we also have
ρ(T ) > ρ0 exp
(∫ T
0
(r − dρ(s)) ds
)
exp(−µu1,max).
Since ρopt(T−) = ρ0 exp
(∫ T
0 (r − dρopt(s)) ds
)
and ρ 6 ρopt, this implies ρ(T ) > ρopt(T ).
Let us now investigate the possible case of equality to prove that the infimum is not at-
tained: the foregoing equality implies that there is equality if and only if
∫ T
0 u ds = u
1,max
(the contraint is saturated) and exp
(∫ T
0 (r − dρ(s)) ds
)
= exp
(∫ T
0 (r − dρopt(s)) ds
)
, whence
ρ ≡ ρopt on [0, T ). As ρ is continuous, ρ(T ) would be given by taking u ≡ 0, which is not
optimal.
B.2 Proof of Lemma 4
Proof. To account for the L1 constraint (C1), we augment the system by defining another
state variable y, whose dynamics are given by dydt = u, leading to:
dρ
dt
= (r − dρ− µu)ρ, dy
dt
= u,
ρ(0) = ρ0, y(0) = 0.
(56)
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The constraint (C1) thus rewrites y(T ) 6 u1,max.
According to the Pontryagin maximum principle (see [54]), there exist absolutely continu-
ous adjoint variables pρ and py on [0, T ], and p0 6 0, such that:
dpρ
dt
= −∂H
∂ρ
= −(r − 2dρ− µu) pρ,
dpy
dt
= −∂H
∂y
= 0 (57)
where the Hamiltonian is
H(ρ, y, pρ, py, u) := pρ (r − dρ− µu) ρ+ pyu = (r − dρ) pρ + u (py − µpρρ) .
Thus, py is some constant, and pρ does not change sign on [0, T ].
The maximisation of the Hamiltonian leads to defining the switching function φ := py −
µpρρ. u is thus equal to u∞,max whenever φ > 0, equal to 0 whenever φ < 0.
The transversality condition is that the vector
(
pρ
py
)
(T ) −p0
(
1
0
)
must be orthogonal to
the tangent space of {(p, y) ∈ R2, y 6 u1,max} at the point (ρ(T ), y(T )).
First case.
If y(T ) < u1,max, then the transversality conditions imply pρ(T ) = p0 and py ≡ 0. p0 6= 0
since otherwise we would have (pρ, py, p0) ≡ 0. Thus, in this case, pρ(T ) < 0 and pρ is
negative on the interval [0, T ]. The switching function φ is therefore positive on the whole
[0, T ], which would imply u ≡ u∞,max. This is a contradiction since a consequence is∫ T
0 u(s) ds = u
∞,maxT > u1,max.
Second case.
If y(T ) = u1,max, we still have pρ(T ) = p0. As in the first case, we cannot have py = 0.
Let us first remark that φ cannot be positive nor negative on the whole interval, since
otherwise u ≡ u∞,max, a contradiction, or u ≡ 0, which is clearly not optimal. If p0 = 0,
pρ ≡ 0, so that φ has the sign of py 6= 0, a contradiction. Therefore, pρ < 0 on [0, T ] as
before, and this implies py < 0 to ensure that φ changes sign.
The derivative of φ is given by dφdt = −µdpρρ
2 > 0. Thus, φ is increasing and u is bang-
bang with one switching only. The fact that y(T ) =
∫ T
0 u(s) ds = u
1,max imposes that this
switching happens at T1(T ) as announced, which ends the proof.
C Proof of Proposition 2
Proof. If the constraint (10) does not saturate on the whole [0, tf ], we distinguish on
whether the last arc is a free arc or a boundary arc on (11).
First case: the last arc is a boundary arc on (11), not reduced to a singleton.
In this case, tM = tf and there can be a jump on the adjoint vector at tf .
41
Let us start by proving the following:
Lemma 6. p0 < 0.
Proof. We argue by contradiction and assume p0 = 0. We first look at the interval
[tM−1, tf ], and assume, also by contradiction, that νM > 0. Then pH(t−f ) = −νM < 0,
hence p′C(t
−
f ) < 0, leading to pC > 0 in a right neighbourhood of tf . From assumption
(51), this means that ρC decreases locally around tf , a contradiction since tf is free (a
better strategy would be to stop before ρC starts increasing): νM = 0.
Now, let us prove that pH , pC and η1 vanish identically on [tM−1, tf ]. If we have pC(t0) > 0
(resp., pC(t0) < 0) for some t0 ∈ [tM−1, tf ), we define the maximal interval [t0, t?) on which
pC > 0 (resp., pC < 0), with pC(t?) = 0. In this case, we know that the switching function
φ1 vanishes on [t0, t?], hence pH factorises with pC . Coming back to the equation on pC , we
have p′C = βCpC on (t0, t
?), for some function βC . Since pC(t?) = 0, this imposes pC ≡ 0
on the interval, a contradiction. Thus pC is identically 0 on the whole (tM−1, tf ), and so
are pH (from the equation on pC) and η1 (from the equation on pH).
We now analyse the arc [tM−2, tM−1]. From the previous step, we know that φ1(tM−1) = 0.
If νM−1 > 0, then φ1(t−M−1) < φ1(tM−1) = 0, thus u1 = u
max
1 locally on the left of tM−1.
Similarly, maximising ψ(u2) imposes u2 = umax2 . Also, H (tM−1) = 0, and H
(
t−M−1
)
=
−νM−1RH
(
t−M−1
)
ρH(tM−1). By continuity of the Hamiltonian, we get RH
(
t−M−1
)
= 0.
At the left of tM−1, u1 and u2 saturate at their maximal values. At the right of tM−1,
RH = 0 but this imposes u1 < umax1 or u2 < umax2 since, owing to (34), ρH decreases for
the maximal values. Thus, 0 = RH
(
t−M−1
)
< RH(tM−1) = 0, a contradiction. Finally, we
have proved νM−1 = 0.
Standard Cauchy-Lispchitz arguments, together with the result pH(t−M−1) = pC(t
−
M−1) = 0
yield that pH and pC are also identically null on the interval [tM−2, tM−1]. Repeating these
arguments on the whole [0, tf ], we find that p, p0, η1, η2 and the (νi)i=1,...,M are all zero,
in contradiction with condition 1 given by the PMP (see Section 3).
Thus p0 < 0 and we set p0 = −1. This normalisation is allowed because the final adjoint
vector (p(tf ), p0) is defined up to scaling. Again, we start by analysing the PMP on
[tM−1, tf ]. From pC(tf ) < 0, we know that u2 = umax2 and φ1 = 0 locally around tf . This
implies pH > 0 also locally around tf . In particular, νM = 0. Using the same reasoning as
before with p′C = βCpC , we get this time that pC and pH have constant sign on (tM−1, tf ):
pC < 0 and pH > 0.
Let us now first assume νM−1 > 0. Then φ1(t−M−1) < 0, leading to u1 = u
max
1 close to
tM−1. If νM−1 is such that pH
(
t−M−1
)
6 0, then clearly the maximisation of ψ(u2) leads to
u2 = u
max
2 . At tM−1, we would thus have continuity of u2 and not u1 since u1 < umax1 on
[tM−1, tf ] from assumption (49). In such a case, it holds true that there can be no jump
on the adjoint vector (see for instance [8]), which is contradictory unless νM−1 is such that
pH
(
t−M−1
)
> 0, which we assume from now on.
42
Let us now analyse the interval [tM−2, tM−1], on which we will prove that u1 = umax1 ,
u2 = u
max
2 . Because η1 and η2 vanish on such an interval, it is easy to prove from standard
Cauchy-Lipschitz uniqueness arguments that pC < 0 and pH > 0 on [tM−2, tM−1]. Also,
because of (44) the inequality
ρC
ρH
<
µH
µC
µCaHHdH − µHaCHdC
µHaCCdC − µCaHCdH
(58)
is satisfied on [0, tf ]. Let us prove that this implies φ1 < 0 on (tM−2, tM−1). For that
purpose, we will prove that whenever φ1(t0) = 0, its derivative satisfies φ′1(t0) > 0. Note
that we already know that φ1(t−M−1) 6 φ1(tM−1) = 0. For such a time t0 we indeed obtain
φ′1(t0) = −
(pCρC) (t0)
µH
[
µH
(
µCaHHdH − µHaCHdC
)
ρH(t0)
− µC
(
µHaCCdC − µCaHCdH
)
ρC(t0)
]
.
Combined with (58), this yields φ′1(t0) > 0, as announced. Thus u1 = umax1 on the whole
[tM−2, tM−1].
For u2, the proof is a bit more involved because the dependence is not linear. In what
follows, we generically denote φ(λH , λC) = λHpHρH+λCpCρC for positive constants λH , λC .
With this notation the previous established result writes φ(µH , µC) < 0 on (tM−2, tM−1).
We need to maximise ψ(u2) = rHpHρH1+αHu2 +
rCpCρC
1+αCu2
as a function of u2, whose derivative has
the opposite sign of P (u2), where
P (u) := αHαCφ(αCrH , αHrC) u
2 + 2(αHαC)φ(rH , rC) u+ φ(αHrH , αCrC),
which has discriminant ∆ = −αHαCrHpHρHrCpCρC(αC − αH)2 > 0 on (0, tf ). We
consider two cases, depending on the sign of φ(αCrH , αHrC). Note that (8) implies the order
φ(αHrH , αCrC) < φ(rH , rC) < φ(αCrH , αHrC). From (46) and φ1 < 0, P (0) = φ(αHrH , αCrC) <
0.
Let us first assume φ(αCrH , αHrC) < 0, in which case all the coefficients of the polynomial
are negative. Let us denote u+ the greater root of this polynomial. Since the coefficient in
front of u2 is negative, the function ψ is increasing with u2 on (u+,+∞). We cannot have
u+ > 0 because of the signs of the coefficients: umax2 maximises the function of interest. If
φ(αCrH , αHrC) = 0, it is easy to see that the same result holds.
Now, let us assume that φ(αCrH , αHrC) > 0. Because P (0) < 0, P (u
max
2 ) < 0 is a sufficient
condition for umax2 to maximise ψ(u2). For any λH > 0, λC > 0, φ1 < 0 leads to φ(λH , λC) <
(λHµC − λCµH)pHρHµC . Applying this to P (u
max
2 ), we find
P (umax2 ) <
pHρH
µC
(
αHαC(αCrHµC − αHrCµH) (umax2 )
2
+2(αHαC)(rHµC − rCµH)umax2 +(αHrHµC − αCrCµH)
)
.
We conclude that P (umax2 ) < 0 thanks to (47).
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Thus, we have proved that, on (tM−2, tM−1), u1 = umax1 and u2 = umax2 . Note that the
result actually implies νM−1 = 0. However the same reasoning with νM−1 = 0 works and
we obtain u1 = umax1 and u2 = umax2 . From assumption (34),
ρC
ρH
increases backwards.
If this ratio reaches the value γ, i.e., if the system saturates the constraint (10) (if not,
tM−2 = 0), then we have a potential boundary arc on (10) on (tM−3, tM−2).
Second case: the last arc is a boundary arc on (11), reduced to a singleton.
Note that, again, tM = tf . This case is handled as the previous one: p0 cannot be 0 and
φ1(t
−
f ) 6 0. Because of this result, the whole reasoning made above in the previous case
applies: there is an unconstrained arc with u1 = umax1 and umax2 . If there is a previous arc,
it is a constrained arc on (10).
Third case: the last arc is a free arc.
Again, the same kind of arguments are enough to prove that p0 < 0, and u1 = umax1 and
umax2 on this arc. If there is a previous arc, it is a constrained arc on (10).
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